Transforming Growth Factor-β Signaling in Immunity and Cancer.

[1]  M. Ehlers,et al.  TGF-β Signaling Specifies Axons during Brain Development , 2010, Cell.

[2]  J. Wolchok,et al.  Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment , 2017, Science Signaling.

[3]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[4]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[5]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[6]  S. Wahl,et al.  Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[8]  J. Massagué,et al.  Structural determinants of Smad function in TGF-β signaling. , 2015, Trends in biochemical sciences.

[9]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[10]  S. Park,et al.  Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2 , 2007, Nature Immunology.

[11]  S. Howie,et al.  Human Dendritic Cells Produce TGF-β1 under the Influence of Lung Carcinoma Cells and Prime the Differentiation of CD4+CD25+Foxp3+ Regulatory T Cells1 , 2009, The Journal of Immunology.

[12]  K. Koike,et al.  TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota , 2017, Journal of Gastroenterology.

[13]  E. Shevach,et al.  Absent C3a and C5a receptor signaling into CD4+ T cells enables auto-inductive TGF-β1 signaling and induction of Foxp3+ T regulatory cells , 2012, Nature Immunology.

[14]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[15]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[16]  P. Bose,et al.  TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure , 2018, Nature Communications.

[17]  S. Park,et al.  Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes , 2013, EMBO molecular medicine.

[18]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[19]  E. Fuchs,et al.  Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. , 2007, Cancer cell.

[20]  Xin Chen,et al.  A transcriptional partner for MAD proteins in TGF-β signalling , 1996, Nature.

[21]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[22]  J. Massagué,et al.  The p53 Family Coordinates Wnt and Nodal Inputs in Mesendodermal Differentiation of Embryonic Stem Cells. , 2017, Cell stem cell.

[23]  C. Iacobuzio-Donahue,et al.  TGF-β Tumor Suppression through a Lethal EMT , 2016, Cell.

[24]  B. Loeys,et al.  Marfan Syndrome and Related Disorders: 25 Years of Gene Discovery , 2016, Human mutation.

[25]  T. Sjöblom,et al.  Sustained TGFβ exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis , 2007, Oncogene.

[26]  David K. Finlay,et al.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway , 2016, Science Signaling.

[27]  Li Yang,et al.  Inflammation-Mediated Genetic and Epigenetic Alterations Drive Cancer Development in the Neighboring Epithelium upon Stromal Abrogation of TGF-β Signaling , 2013, PLoS genetics.

[28]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[29]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[30]  G. Natoli,et al.  Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB , 2009, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Stavnezer,et al.  Analysis of transforming growth factor‐β1‐induced Ig germ‐line γ2b transcription and its implication for IgA isotype switching , 2005, European journal of immunology.

[32]  C. Drachenberg,et al.  TGF-β–dependent CD103 expression by CD8+ T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease , 2005, The Journal of experimental medicine.

[33]  J. Massagué,et al.  Transforming growth factor (cid:1) -induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation , 2022 .

[34]  D. Gabrilovich.  Myeloid-Derived Suppressor Cells , 2017, Cancer Immunology Research.

[35]  T. Curiel,et al.  Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells , 2017, Nature Communications.

[36]  Yue Zhang,et al.  Regulation of the Polarity Protein Par6 by TGFß Receptors Controls Epithelial Cell Plasticity , 2005, Science.

[37]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[38]  Y. Wan,et al.  T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. , 2007, Immunity.

[39]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[40]  E. Fuchs,et al.  The harmonies played by TGF-β in stem cell biology. , 2012, Cell stem cell.

[41]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[42]  Ken W. Y. Cho,et al.  Foxh1 Occupies cis-Regulatory Modules Prior to Dynamic Transcription Factor Interactions Controlling the Mesendoderm Gene Program. , 2017, Developmental cell.

[43]  A. Kulkarni,et al.  A critical function for TGF-β signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells , 2008, Nature Immunology.

[44]  B. R. Achyut,et al.  Gr‐1+CD11b+ cells are responsible for tumor promoting effect of TGF‐β in breast cancer progression , 2012, International journal of cancer.

[45]  Dong-Wan Kim,et al.  Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1 , 2004, The Journal of Immunology.

[46]  J. Gorham,et al.  TGF-β1 Regulates Antigen-Specific CD4+ T Cell Responses in the Periphery1 , 2007, The Journal of Immunology.

[47]  S. Barry,et al.  Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors , 2018, Molecular Pharmacology.

[48]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Coppola,et al.  TGF-β–inducible microRNA-183 silences tumor-associated natural killer cells , 2014, Proceedings of the National Academy of Sciences.

[50]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[51]  Naoto Hirano,et al.  Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells , 2001, Nature Immunology.

[52]  J. Orenstein,et al.  Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. , 2005, The Journal of clinical investigation.

[53]  S. Vidal,et al.  TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy , 2012, Nature Immunology.

[54]  J. Madore,et al.  CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment , 2018, Clinical Cancer Research.

[55]  Yibin Kang,et al.  Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. , 2011, Cancer cell.

[56]  P. Delvenne,et al.  Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo , 2015, Science Translational Medicine.

[57]  T. Schumacher,et al.  Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer , 2013, The Journal of Immunology.

[58]  T. Mosmann,et al.  Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. , 1994, Journal of immunology.

[59]  H. Moses,et al.  TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment. , 2017, Cold Spring Harbor perspectives in biology.

[60]  S. Wahl,et al.  Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta , 1990, The Journal of experimental medicine.

[61]  J. Weiss,et al.  TGF-β signaling in myeloid cells is required for tumor metastasis. , 2013, Cancer discovery.

[62]  M. Colonna,et al.  SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling , 2017, Nature Immunology.

[63]  C. Heldin,et al.  The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner , 2008, Nature Cell Biology.

[64]  A. Zhavoronkov,et al.  Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy , 2018, Nature Communications.

[65]  Jack T. Lin,et al.  TGF-β1 Uses Distinct Mechanisms to Inhibit IFN-γ Expression in CD4+ T Cells at Priming and at Recall: Differential Involvement of Stat4 and T-bet1 , 2005, The Journal of Immunology.

[66]  D. Pellicci,et al.  T-box Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate. , 2015, Immunity.

[67]  J. Tabernero,et al.  Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer , 2018, British Journal of Cancer.

[68]  G. Giannelli,et al.  A phase 2 study of a novel transforming growth factor-beta (TGF-{beta}1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). , 2014 .

[69]  Xin-Hua Feng,et al.  Smad2 Positively Regulates the Generation of Th17 Cells* , 2010, The Journal of Biological Chemistry.

[70]  M. Yamashita,et al.  TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. , 2008, Molecular cell.

[71]  Richard A. Flavell,et al.  Mechanism of Transforming Growth Factor β–induced Inhibition of T Helper Type 1 Differentiation , 2002, The Journal of experimental medicine.

[72]  D. Sheppard,et al.  Epithelial cells utilize cortical actin/myosin to activate latent TGF-β through integrin α(v)β(6)-dependent physical force. , 2012, Experimental cell research.

[73]  J. Wolchok,et al.  Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation , 2015, Nature Communications.

[74]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[75]  J. Baselga,et al.  Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study , 2014, Cardiovascular Toxicology.

[76]  D. Rifkin,et al.  Integrin αVβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1 , 2004, The Journal of cell biology.

[77]  R. Biassoni,et al.  Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Dean Sheppard,et al.  TGF-β activation and function in immunity. , 2014, Annual review of immunology.

[79]  Takeshi Imamura,et al.  Role of Ras Signaling in the Induction of Snail by Transforming Growth Factor-β* , 2009, Journal of Biological Chemistry.

[80]  T. Walz,et al.  Latent TGF-β structure and activation , 2011, Nature.

[81]  J. Massagué,et al.  Contextual determinants of TGFβ action in development, immunity and cancer , 2018, Nature Reviews Molecular Cell Biology.

[82]  J. Downward,et al.  Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis , 2002, The Journal of Cell Biology.

[83]  J. Pollard,et al.  A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.

[84]  Xin-Yuan Fu,et al.  Smad4 signalling in T cells is required for suppression of gastrointestinal cancer , 2006, Nature.

[85]  D. Klatzmann,et al.  TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. , 2016, JCI insight.

[86]  I. Melero,et al.  TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies , 2019, Molecular Cancer Therapeutics.

[87]  Y. Zu,et al.  Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Transforming Growth Factor β1 Inhibits Fas Ligand Expression and Subsequent Activation-induced Cell Death in T Cells via Downregulation of c-Myc , 1999, The Journal of experimental medicine.

[89]  M. Travis,et al.  Regulation of Innate and Adaptive Immunity by TGFβ. , 2017, Advances in immunology.

[90]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[91]  George Q. Daley,et al.  Lineage Regulators Direct BMP and Wnt Pathways to Cell-Specific Programs during Differentiation and Regeneration , 2011, Cell.

[92]  J. Wrana,et al.  TGF-β Family Signaling in Embryonic and Somatic Stem-Cell Renewal and Differentiation. , 2017, Cold Spring Harbor perspectives in biology.

[93]  J. Ting,et al.  Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. , 1998, Journal of immunology.

[94]  E. Tartour,et al.  Resident memory T cells, critical components in tumor immunology , 2018, Journal of Immunotherapy for Cancer.

[95]  D. Carbone,et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.

[96]  S. Rosenberg,et al.  TGF-β1 Attenuates the Acquisition and Expression of Effector Function by Tumor Antigen-Specific Human Memory CD8 T Cells , 2005, The Journal of Immunology.

[97]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[98]  S. Savvides,et al.  Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells , 2018, Science.

[99]  N. Minato,et al.  SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion , 2007, Nature Genetics.

[100]  Yuelei Shen,et al.  TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function , 2008, Nature.

[101]  R. Flavell,et al.  Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms , 2006 .

[102]  E. Shevach,et al.  GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[103]  Ximing J. Yang,et al.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.

[104]  A. Kulkarni,et al.  Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. , 1996, The Journal of clinical investigation.

[105]  R. Schwartz,et al.  Smad3 Is Essential for TGF-β1 to Suppress IL-2 Production and TCR-Induced Proliferation, but Not IL-2-Induced Proliferation1 , 2004, The Journal of Immunology.

[106]  K. Furuuchi,et al.  Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer , 2008, Nature Immunology.

[107]  S. Bicciato,et al.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells , 2011, Nature Immunology.

[108]  L. Boon,et al.  Cutting Edge: Autocrine TGF-β Sustains Default Tolerogenesis by IDO-Competent Dendritic Cells1 , 2008, The Journal of Immunology.

[109]  A. Rao,et al.  Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs , 2009, The Journal of experimental medicine.

[110]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[111]  Gerald C. Chu,et al.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. , 2006, Genes & development.

[112]  B. Becher,et al.  TGF-β Signalling Is Required for CD4+ T Cell Homeostasis But Dispensable for Regulatory T Cell Function , 2013, PLoS biology.

[113]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[114]  J. Ting,et al.  Identification of Distinct Regions of 5′ Flanking DNA That Mediate Constitutive, IFN-γ, STAT1, and TGF-β-Regulated Expression of the Class II Transactivator Gene , 1998, The Journal of Immunology.

[115]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[116]  N. Waddell,et al.  Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells , 2017, Nature Immunology.

[117]  M. Bevan,et al.  Transforming growth factor-β signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. , 2013, Immunity.

[118]  Peter R. Galle,et al.  Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 , 2004, The Journal of Immunology.

[119]  A. Hata,et al.  SMAD proteins control DROSHA-mediated microRNA maturation , 2008, Nature.

[120]  A. Rudensky,et al.  Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. , 2006, Immunity.

[121]  B. Comin-Anduix,et al.  Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer , 2018, Clinical Cancer Research.

[122]  P. Howe,et al.  Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. , 2016, Cancer research.

[123]  Ralph Weissleder,et al.  Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. , 2006, Immunity.

[124]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[125]  Yifan Cheng,et al.  Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. , 2018, JCI insight.

[126]  D. Sheppard,et al.  Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8 , 2017, Proceedings of the National Academy of Sciences.

[127]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[128]  Austin Miller,et al.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. , 2013, Cancer research.

[129]  J. Letterio,et al.  p21Cip1 and p27Kip1 Act in Synergy to Alter the Sensitivity of Naive T Cells to TGF-β-Mediated G1 Arrest through Modulation of IL-2 Responsiveness , 2004, The Journal of Immunology.

[130]  David A. Orlando,et al.  Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-β Signaling , 2011, Cell.

[131]  Elisa de Stanchina,et al.  Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT , 2016, Cell.

[132]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[133]  J. Allison,et al.  T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. , 2011, Immunity.

[134]  Richard A Flavell,et al.  Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. , 2008, Immunity.

[135]  F. X. Qin,et al.  Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells , 2007, Proceedings of the National Academy of Sciences.

[136]  C. Heldin,et al.  Signaling Receptors for TGF-β Family Members. , 2016, Cold Spring Harbor Perspectives in Biology.

[137]  A. Sette,et al.  Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. , 1995, Immunity.

[138]  B. Chauffert,et al.  Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation , 2005, The Journal of experimental medicine.

[139]  A. Iavarone,et al.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. , 1995, Genes & development.

[140]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[141]  R. Bronson,et al.  A Milieu Molecule for TGF-β Required for Microglia Function in the Nervous System , 2018, Cell.

[142]  L. Lanier,et al.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. , 2010, Neuro-oncology.

[143]  S. Park,et al.  Smad6-specific recruitment of Smurf E3 ligases mediates TGF-β1-induced degradation of MyD88 in TLR4 signalling. , 2011, Nature communications.

[144]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[145]  M. Aoki,et al.  Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model , 2010, Proceedings of the National Academy of Sciences.

[146]  M. Hennig,et al.  Platelets subvert T cell immunity against cancer via GARP-TGFβ axis , 2017, Science Immunology.

[147]  B. Hinz,et al.  Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix , 2007, The Journal of cell biology.

[148]  F. Sutterwala,et al.  Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ , 2005, Nature Immunology.

[149]  S. Zheng,et al.  Dendritic Cell-Specific Disruption of TGF-β Receptor II Leads to Altered Regulatory T Cell Phenotype and Spontaneous Multiorgan Autoimmunity , 2012, The Journal of Immunology.

[150]  Craig P. McEntee,et al.  Human monocytes and macrophages regulate immune tolerance via integrin αvβ8–mediated TGFβ activation , 2018, The Journal of experimental medicine.

[151]  R. Stein,et al.  Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[152]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[153]  Shuang Chen,et al.  Transforming Growth Factor-β Differentially Inhibits MyD88-dependent, but Not TRAM- and TRIF-dependent, Lipopolysaccharide-induced TLR4 Signaling* , 2005, Journal of Biological Chemistry.

[154]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[155]  J. Chirgwin,et al.  Transforming Growth Factor-Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways * , 2002 .

[156]  J. Massagué,et al.  E2F4/5 and p107 as Smad Cofactors Linking the TGFβ Receptor to c-myc Repression , 2002, Cell.

[157]  Ming O. Li,et al.  Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection. , 2017, Cold Spring Harbor perspectives in biology.

[158]  M. Bevan,et al.  Transforming growth factor-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation , 2012, Nature Immunology.

[159]  M. Caligiuri,et al.  Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. , 2006, Immunity.

[160]  A. Balmain,et al.  α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas , 2019, Journal of Immunotherapy for Cancer.

[161]  D. Sheppard,et al.  TGF-β1 Signaling and Tissue Fibrosis. , 2018, Cold Spring Harbor perspectives in biology.

[162]  H. Weiner,et al.  Targeting latency-associated peptide promotes antitumor immunity , 2017, Science Immunology.

[163]  A. Kulkarni,et al.  Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse. , 1999, Journal of immunology.

[164]  N. Reiner,et al.  TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. , 1997, Journal of immunology.

[165]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[166]  P. Iversen,et al.  Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade , 2018, Journal of Immunotherapy for Cancer.

[167]  A. Fattorossi,et al.  Interleukin‐21 (IL‐21) synergizes with IL‐2 to enhance T‐cell receptor‐induced human T‐cell proliferation and counteracts IL‐2/transforming growth factor‐β‐induced regulatory T‐cell development , 2013, Immunology.

[168]  Jing Qing,et al.  TGF‐β activates Erk MAP kinase signalling through direct phosphorylation of ShcA , 2007 .

[169]  T. Wirth,et al.  Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site , 1993, Molecular and cellular biology.

[170]  R. Morita,et al.  Smad2 and Smad3 Are Redundantly Essential for the TGF-β–Mediated Regulation of Regulatory T Plasticity and Th1 Development , 2010, The Journal of Immunology.

[171]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[172]  F. Jirik,et al.  Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. , 2011, The Journal of clinical investigation.

[173]  P. Dijke,et al.  Immunoregulation by members of the TGFβ superfamily , 2016, Nature Reviews Immunology.

[174]  T. Springer,et al.  GARP regulates the bioavailability and activation of TGFβ , 2012, Molecular biology of the cell.

[175]  Joseph C. Sun,et al.  Transforming Growth Factor-β Signaling Guides the Differentiation of Innate Lymphoid Cells in Salivary Glands. , 2016, Immunity.

[176]  D. Greaves,et al.  TGF‐β limits IL‐33 production and promotes the resolution of colitis through regulation of macrophage function , 2011, European journal of immunology.

[177]  A. Durán,et al.  Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance , 2018, Immunity.

[178]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[179]  J. Zavadil,et al.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.

[180]  T. Eberlein,et al.  Tumor-derived TGF-β Mediates Conversion of CD4+Foxp3+ Regulatory T Cells in a Murine Model of Pancreas Cancer , 2009, Journal of immunotherapy.

[181]  Y. Li,et al.  Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor β–Insensitive CD8+ T Cells , 2009, Clinical Cancer Research.

[182]  C. Augustine,et al.  Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. , 2013, The Journal of clinical investigation.

[183]  Simon C Watkins,et al.  Transforming Growth Factor Blocks Tec Kinase Phosphorylation , Ca 2 Influx , and NFATc Translocation Causing Inhibition of T Cell Differentiation , 2003 .

[184]  S. Park,et al.  Smad6 negatively regulates interleukin 1-receptor–Toll-like receptor signaling through direct interaction with the adaptor Pellino-1 , 2006, Nature Immunology.

[185]  Hao Shen,et al.  Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin , 2003, Science.